- Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumabPriti S Hegde
Department of Oncology Biomarkers, Genentech, Inc, South San Francisco, CA 94080, USA
Clin Cancer Res 19:929-37. 2013..We evaluated the prognostic and predictive use of circulating VEGF-A levels in phase III trials of bevacizumab in colorectal cancer, lung cancer, and renal cell carcinoma...
- Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myelomaCongfen Li
Genentech Inc, South San Francisco, CA 94080, USA
J Transl Med 11:76. 2013..This study aimed to develop a robust clinical pharmacodynamic (PD) assay to measure the on-target PD effects of the selective PI3K inhibitor GDC-0941 in MM patients...